Wedbush Issues Pessimistic Forecast for Aprea Therapeutics (NASDAQ:APRE) Stock Price

Aprea Therapeutics (NASDAQ:APRE) had its price target dropped by analysts at Wedbush from $6.00 to $3.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush’s price target would suggest a potential upside of 339.24% from the stock’s current price.

APRE has been the subject of a number of other research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Friday, July 17th. Oppenheimer assumed coverage on shares of Aprea Therapeutics in a research note on Thursday, May 7th. They issued an “outperform” rating and a $5.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $3.07.

Aprea Therapeutics Price Performance

NASDAQ APRE opened at $0.68 on Thursday. The company has a market capitalization of $8.46 million, a PE ratio of -0.44 and a beta of 1.52. The company has a fifty day moving average of $0.71 and a 200 day moving average of $0.77. Aprea Therapeutics has a 1 year low of $0.55 and a 1 year high of $1.79.

Aprea Therapeutics (NASDAQ:APRE) last posted its earnings results on Wednesday, August 12th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.11. Aprea Therapeutics had a negative net margin of 4,405.59% and a negative return on equity of 61.03%. Research analysts expect that Aprea Therapeutics will post -0.84 earnings per share for the current year.

Institutional Trading of Aprea Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. DRW Securities LLC acquired a new position in Aprea Therapeutics in the fourth quarter valued at approximately $103,000. Jane Street Group LLC acquired a new stake in shares of Aprea Therapeutics in the fourth quarter valued at $40,000. Finally, AIGH Capital Management LLC grew its stake in Aprea Therapeutics by 174.1% during the 1st quarter. AIGH Capital Management LLC now owns 1,015,541 shares of the company’s stock worth $775,000 after purchasing an additional 645,000 shares in the last quarter. 34.19% of the stock is owned by institutional investors and hedge funds.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.